Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS.
Identifieur interne : 000177 ( PubMed/Checkpoint ); précédent : 000176; suivant : 000178Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS.
Auteurs : Mohsen Rokni [Iran] ; Vida Ghasemi [Iran] ; Zahra Tavakoli [Iran]Source :
- Reviews in medical virology [ 1099-1654 ] ; 2020.
Abstract
The beginning of 2020 has seen the emergence of COVID-19, an outbreak caused by a novel coronavirus, SARS-CoV-2, an important pathogen for humans. There is an urgent need to better understand this new virus and to develop ways to control its spread. In Iran, the first case of the COVID-19 was reported after spread from China and other countries. Fever, cough, and fatigue were the most common symptoms of this virus. In worldwide, the incubation period of COVID-19 was 3 to 7 days and approximately 80% of infections are mild or asymptomatic, 15% are severe, requiring oxygen, and 5% are critical infections, requiring ventilation. To mount an antiviral response, the innate immune system recognizes molecular structures that are produced by the invasion of the virus. COVID-19 infection induces IgG antibodies against N protein that can be detected by serum as early as day 4 after the onset of disease and with most patients seroconverting by day 14. Laboratory evidence of clinical patients showed that a specific T-cell response against SARS-CoV-2 is important for the recognition and killing of infected cells, particularly in the lungs of infected individuals. At present, there is no specific antiviral therapy for COVID-19 and the main treatments are supportive. In this review, we investigated the innate and acquired immune responses in patients who recovered from COVID-19, which could inform the design of prophylactic vaccines and immunotherapy for the future.
DOI: 10.1002/rmv.2107
PubMed: 32267987
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:32267987Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS.</title><author><name sortKey="Rokni, Mohsen" sort="Rokni, Mohsen" uniqKey="Rokni M" first="Mohsen" last="Rokni">Mohsen Rokni</name><affiliation wicri:level="1"><nlm:affiliation>Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Ghasemi, Vida" sort="Ghasemi, Vida" uniqKey="Ghasemi V" first="Vida" last="Ghasemi">Vida Ghasemi</name><affiliation wicri:level="1"><nlm:affiliation>Student Research Committee, Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Student Research Committee, Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Tavakoli, Zahra" sort="Tavakoli, Zahra" uniqKey="Tavakoli Z" first="Zahra" last="Tavakoli">Zahra Tavakoli</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology, School of Medicine, Lorestan University of Medical Sciences, Khoramabad, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Department of Virology, School of Medicine, Lorestan University of Medical Sciences, Khoramabad</wicri:regionArea><wicri:noRegion>Khoramabad</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32267987</idno><idno type="pmid">32267987</idno><idno type="doi">10.1002/rmv.2107</idno><idno type="wicri:Area/PubMed/Corpus">000065</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000065</idno><idno type="wicri:Area/PubMed/Curation">000065</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000065</idno><idno type="wicri:Area/PubMed/Checkpoint">000177</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000177</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS.</title><author><name sortKey="Rokni, Mohsen" sort="Rokni, Mohsen" uniqKey="Rokni M" first="Mohsen" last="Rokni">Mohsen Rokni</name><affiliation wicri:level="1"><nlm:affiliation>Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Ghasemi, Vida" sort="Ghasemi, Vida" uniqKey="Ghasemi V" first="Vida" last="Ghasemi">Vida Ghasemi</name><affiliation wicri:level="1"><nlm:affiliation>Student Research Committee, Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Student Research Committee, Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Tavakoli, Zahra" sort="Tavakoli, Zahra" uniqKey="Tavakoli Z" first="Zahra" last="Tavakoli">Zahra Tavakoli</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology, School of Medicine, Lorestan University of Medical Sciences, Khoramabad, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Department of Virology, School of Medicine, Lorestan University of Medical Sciences, Khoramabad</wicri:regionArea><wicri:noRegion>Khoramabad</wicri:noRegion></affiliation></author></analytic><series><title level="j">Reviews in medical virology</title><idno type="eISSN">1099-1654</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The beginning of 2020 has seen the emergence of COVID-19, an outbreak caused by a novel coronavirus, SARS-CoV-2, an important pathogen for humans. There is an urgent need to better understand this new virus and to develop ways to control its spread. In Iran, the first case of the COVID-19 was reported after spread from China and other countries. Fever, cough, and fatigue were the most common symptoms of this virus. In worldwide, the incubation period of COVID-19 was 3 to 7 days and approximately 80% of infections are mild or asymptomatic, 15% are severe, requiring oxygen, and 5% are critical infections, requiring ventilation. To mount an antiviral response, the innate immune system recognizes molecular structures that are produced by the invasion of the virus. COVID-19 infection induces IgG antibodies against N protein that can be detected by serum as early as day 4 after the onset of disease and with most patients seroconverting by day 14. Laboratory evidence of clinical patients showed that a specific T-cell response against SARS-CoV-2 is important for the recognition and killing of infected cells, particularly in the lungs of infected individuals. At present, there is no specific antiviral therapy for COVID-19 and the main treatments are supportive. In this review, we investigated the innate and acquired immune responses in patients who recovered from COVID-19, which could inform the design of prophylactic vaccines and immunotherapy for the future.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32267987</PMID><DateRevised><Year>2020</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1654</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Apr</Month><Day>08</Day></PubDate></JournalIssue><Title>Reviews in medical virology</Title><ISOAbbreviation>Rev. Med. Virol.</ISOAbbreviation></Journal><ArticleTitle>Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/rmv.2107</ELocationID><Abstract><AbstractText>The beginning of 2020 has seen the emergence of COVID-19, an outbreak caused by a novel coronavirus, SARS-CoV-2, an important pathogen for humans. There is an urgent need to better understand this new virus and to develop ways to control its spread. In Iran, the first case of the COVID-19 was reported after spread from China and other countries. Fever, cough, and fatigue were the most common symptoms of this virus. In worldwide, the incubation period of COVID-19 was 3 to 7 days and approximately 80% of infections are mild or asymptomatic, 15% are severe, requiring oxygen, and 5% are critical infections, requiring ventilation. To mount an antiviral response, the innate immune system recognizes molecular structures that are produced by the invasion of the virus. COVID-19 infection induces IgG antibodies against N protein that can be detected by serum as early as day 4 after the onset of disease and with most patients seroconverting by day 14. Laboratory evidence of clinical patients showed that a specific T-cell response against SARS-CoV-2 is important for the recognition and killing of infected cells, particularly in the lungs of infected individuals. At present, there is no specific antiviral therapy for COVID-19 and the main treatments are supportive. In this review, we investigated the innate and acquired immune responses in patients who recovered from COVID-19, which could inform the design of prophylactic vaccines and immunotherapy for the future.</AbstractText><CopyrightInformation>© 2020 John Wiley & Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rokni</LastName><ForeName>Mohsen</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-0534-4251</Identifier><AffiliationInfo><Affiliation>Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology, Buali Hospital of Laboratory, Zahedan University of Medical Sciences, Zahedan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghasemi</LastName><ForeName>Vida</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Student Research Committee, Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Asad Abad university of Medical Sciences, Hamadan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavakoli</LastName><ForeName>Zahra</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Virology, School of Medicine, Lorestan University of Medical Sciences, Khoramabad, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>12354</GrantID><Agency>Tehran University of Medical Sciences and Health Services</Agency><Country></Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Rev Med Virol</MedlineTA><NlmUniqueID>9112448</NlmUniqueID><ISSNLinking>1052-9276</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">2019-nCoV disease</Keyword><Keyword MajorTopicYN="N">B cell</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">T cell</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">immunity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>03</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>03</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32267987</ArticleId><ArticleId IdType="doi">10.1002/rmv.2107</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Wang LF, Shi Z, Zhang S, Field H, Daszak P, Eaton BT. Review of bats and SARS. Emerg Infect Dis. 2006;12(12):1834-1840.</Citation></Reference><Reference><Citation>Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-269.</Citation></Reference><Reference><Citation>Ge XY, Li JL, Yang XL, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013;503(7477):535-538.</Citation></Reference><Reference><Citation>Zu ZY, Jiang MD, Xu PP, et al. Coronavirus disease 2019 (COVID-19): a perspective from China. Radiology. 2020;200490.</Citation></Reference><Reference><Citation>Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470-473.</Citation></Reference><Reference><Citation>Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):11.</Citation></Reference><Reference><Citation>Angeletti S, Benvenuto D, Bianchi M, Giovanetti M, Pascarella S, Ciccozzi M. COVID-2019: the role of the nsp2 and nsp3 in its pathogenesis. J Med Virol. 2020.</Citation></Reference><Reference><Citation>Shen Z, Xiao Y, Kang L, et al. Genomic diversity of SARS-CoV-2 in coronavirus disease 2019 patients. Clin. Infect. Dis. 2020.</Citation></Reference><Reference><Citation>Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.</Citation></Reference><Reference><Citation>Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514-523.</Citation></Reference><Reference><Citation>Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450-454.</Citation></Reference><Reference><Citation>Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444-1448.</Citation></Reference><Reference><Citation>Sun Z, Thilakavathy K, Kumar SS, He G, Liu SV. Potential factors influencing repeated SARS outbreaks in China. Int. J. Environ. Res. Public Health. 2020;17(5):1633.</Citation></Reference><Reference><Citation>Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424-432.</Citation></Reference><Reference><Citation>Baruah V, Bose S. Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV. J Med Virol. 2020;92(5):495-500.</Citation></Reference><Reference><Citation>Zhang B, Zhou X, Qiu Y, et al. Clinical characteristics of 82 death cases with COVID-19. medRxiv. 2020.</Citation></Reference><Reference><Citation>Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95-103.</Citation></Reference><Reference><Citation>Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies. J. Biol. Regul. Homeostatic Agents. 2020;34(2).</Citation></Reference><Reference><Citation>Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med. 2020:1-5.</Citation></Reference><Reference><Citation>de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523-534.</Citation></Reference><Reference><Citation>Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529-539.</Citation></Reference><Reference><Citation>Deng X, van Geelen A, Buckley AC, et al. Coronavirus Endoribonuclease activity in porcine epidemic diarrhea virus suppresses type I and type III interferon responses. J Virol. 2019;93(8):e02000-18.</Citation></Reference><Reference><Citation>Yang CH, Li K, Pfeffer SR, Pfeffer LM. The type I IFN-induced miRNA, miR-21. Pharmaceuticals. 2015;8(4):836-847.</Citation></Reference><Reference><Citation>Kindler E, Thiel V, Weber F. Interaction of SARS and MERS coronaviruses with the antiviral interferon response. Adv Virus Res. 2016;96:219-243.</Citation></Reference><Reference><Citation>Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38:1-9.</Citation></Reference><Reference><Citation>Gorse GJ, Donovan MM, Patel GB. Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses. J Med Virol. 2020;92(5):512-517.</Citation></Reference><Reference><Citation>Liu W, Fontanet A, Zhang PH, et al. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis. 2006;193(6):792-795.</Citation></Reference><Reference><Citation>Hsueh PR, Huang LM, Chen PJ, Kao CL, Yang PC. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect. 2004;10(12):1062-1066.</Citation></Reference><Reference><Citation>Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020.</Citation></Reference><Reference><Citation>Cameron MJ, Ran L, Xu L, et al. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol. 2007;81(16):8692-8706.</Citation></Reference><Reference><Citation>Tang F, Quan Y, Xin Z-T, et al. Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J Immunol. 2011;186(12):7264-7268.</Citation></Reference><Reference><Citation>Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273.</Citation></Reference><Reference><Citation>Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005;202(3):415-424.</Citation></Reference><Reference><Citation>Channappanavar R, Fett C, Zhao J, Meyerholz DK, Perlman S. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J Virol. 2014;88(19):11034-11044.</Citation></Reference><Reference><Citation>Chen J, Lau YF, Lamirande EW, et al. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J Virol. 2010;84(3):1289-1301.</Citation></Reference><Reference><Citation>Zhao J, Zhao J, Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol. 2010;84(18):9318-9325.</Citation></Reference><Reference><Citation>Li CK, Wu H, Yan H, et al. T cell responses to whole SARS coronavirus in humans. J Immunol. 2008;181(8):5490-5500.</Citation></Reference><Reference><Citation>Fan YY, Huang ZT, Li L, et al. Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection. Arch Virol. 2009;154(7):1093-1099.</Citation></Reference><Reference><Citation>Peng H, Yang LT, Wang LY, et al. Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients. Virology. 2006;351(2):466-475.</Citation></Reference><Reference><Citation>Guan WD, Mok CK, Chen ZL, et al. Characteristics of traveler with Middle East respiratory syndrome, China, 2015. Emerg Infect Dis. 2015;21(12):2278-2280.</Citation></Reference><Reference><Citation>Ng OW, Chia A, Tan AT, et al. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine. 2016;34(17):2008-2014.</Citation></Reference><Reference><Citation>Oh HL, Chia A, Chang CX, et al. Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope. J Virol. 2011;85(20):10464-10471.</Citation></Reference><Reference><Citation>Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr H. Treatment of SARS with human interferons. Lancet. 2003;362(9380):293-294.</Citation></Reference><Reference><Citation>Chen RC, Tang XP, Tan SY, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006;129(6):1441-1452.</Citation></Reference><Reference><Citation>Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-73.</Citation></Reference><Reference><Citation>Baron SA, Devaux C, Colson P, Raoult D, Rolain JM. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19? Int J Antimicrob Agents. 2020;105944.</Citation></Reference><Reference><Citation>Scott LJ. Tocilizumab: a review in rheumatoid arthritis. Drugs. 2017;77(17):1865-1879.</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Iran</li></country></list><tree><country name="Iran"><noRegion><name sortKey="Rokni, Mohsen" sort="Rokni, Mohsen" uniqKey="Rokni M" first="Mohsen" last="Rokni">Mohsen Rokni</name></noRegion><name sortKey="Ghasemi, Vida" sort="Ghasemi, Vida" uniqKey="Ghasemi V" first="Vida" last="Ghasemi">Vida Ghasemi</name><name sortKey="Tavakoli, Zahra" sort="Tavakoli, Zahra" uniqKey="Tavakoli Z" first="Zahra" last="Tavakoli">Zahra Tavakoli</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000177 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000177 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:32267987
|texte= Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:32267987" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |